Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.83
- Piotroski Score 3.00
- Grade Buy
- Symbol (YMAB)
- Company Y-mAbs Therapeutics, Inc.
- Price $14.05
- Changes Percentage (3.92%)
- Change $0.53
- Day Low $13.44
- Day High $14.22
- Year High $20.90
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $21.50
- High Stock Price Target $26.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.49
- Trailing P/E Ratio -24.45
- Forward P/E Ratio -24.45
- P/E Growth -24.45
- Net Income $-21,427,000
Income Statement
Quarterly
Annual
Latest News of YMAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate
Investing in stocks carries risks, but finding a high-quality company like Y-mAbs Therapeutics (YMAB) can yield significant returns. Despite recent fluctuations, its long-term performance and revenue ...
By Yahoo! Finance | 1 week ago -
Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners' Top Holdings Now?
Caligan Partners, a significant specialty hedge fund, focuses on healthcare investments in the US. They engage in activist strategies, pushing for strategic changes in companies to enhance shareholder...
By Yahoo! Finance | 1 month ago -
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Despite losing money, shareholders can profit if they buy a good business at the right price. Y-mAbs Therapeutics has a reassuringly long cash runway of about 4.3 years, showing progress with reduced ...
By Yahoo! Finance | 2 months ago
